IFNA1 and cancer: Data on the impact of IFN therapy (which includes IFN-α and pegylated IFN-α) in HBV-related cancers are contrasting, due to the lack of pre-treatment stratification for cancer predictors and exclusion of patients at higher risk of developing HCC, as those unfit for IFN due to advanced liver disease.